Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuli Li

Showing results (201-210 of 233) with videos related to

Pageof 24
Sort By:
Cancer|August 9, 2017
Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590)Aarti K Bhatia, Ju-Whei Lee, Harlan A Pinto, et al.
Transplantation and Cellular Therapy|April 12, 2021
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationEvan C Chen, Shuli Li, Ann-Kathrin Eisfeld, et al.
Blood|June 2, 2019
Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failureYi-Bin Chen, Nahel Elias, Eliot Heher, et al.
Bone Research|December 17, 2019
Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossificationCharles Hwang, Simone Marini, Amanda K Huber, et al.
Cancer|September 11, 2014
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphomaYi-Bin Chen, Tracy Batchelor, Shuli Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2021
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)Robert L Ferris, Yael Flamand, Gregory S Weinstein, et al.
Blood|April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myelomaSarah A Holstein, Shebli Atrash, Hira Mian, et al.
Nature Communications|February 7, 2020
Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healingMichael Sorkin, Amanda K Huber, Charles Hwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494Jane N Winter, Shuli Li, Vikas Aurora, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 21, 2014
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemiaYi-Bin Chen, Shuli Li, Andrew A Lane, et al.
Pageof 24

Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
Cancer|August 9, 2017
Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590)Aarti K Bhatia, Ju-Whei Lee, Harlan A Pinto, et al.
Transplantation and Cellular Therapy|April 12, 2021
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationEvan C Chen, Shuli Li, Ann-Kathrin Eisfeld, et al.
Blood|June 2, 2019
Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failureYi-Bin Chen, Nahel Elias, Eliot Heher, et al.
Bone Research|December 17, 2019
Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossificationCharles Hwang, Simone Marini, Amanda K Huber, et al.
Cancer|September 11, 2014
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphomaYi-Bin Chen, Tracy Batchelor, Shuli Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2021
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)Robert L Ferris, Yael Flamand, Gregory S Weinstein, et al.
Blood|April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myelomaSarah A Holstein, Shebli Atrash, Hira Mian, et al.
Nature Communications|February 7, 2020
Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healingMichael Sorkin, Amanda K Huber, Charles Hwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494Jane N Winter, Shuli Li, Vikas Aurora, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 21, 2014
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemiaYi-Bin Chen, Shuli Li, Andrew A Lane, et al.
Pageof 24